Abstract
MicroRNAs (miRNAs) are an abundant class of approximately 22-nucleotide – noncoding RNAs, which play important regulatory roles in animal and plant development: they are involved in gene expression at the posttranscriptional level by degrading or blocking translation of messenger RNA (mRNA) targets. miRNAs can induce RNA cleavage and chromatin modifications, and are implicated in apoptotic pathways and regulation of cell growth and proliferation. It is becoming clear that miRNAs play important roles in the regulation of gene expression during development, and our knowledge of the expression levels or function of miRNAs in normal and neoplastic cells is increasing. Accumulating experimental evidence suggests that different miRNAs are deregulated in primary human tumors and that many human miRNAs are located at genomic regions linked to cancer. miRNAs may be important regulators of mammalian hematopoiesis. They are involved in a variety of hematological malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and primary effusion lymphoma. Here, we provide background on the biogenesis and function of miRNAs and discuss potential therapeutic applications of miRNA-based technology in hematological malignancies.
Keywords: microRNA, non-coding RNA, RNA interference, molecular biology, oncogenes, tumor suppressors, haematological malignancies, potential therapeutic applications
Current Pharmaceutical Design
Title: Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies
Volume: 14 Issue: 21
Author(s): Elisa Barbarotto and George A. Calin
Affiliation:
Keywords: microRNA, non-coding RNA, RNA interference, molecular biology, oncogenes, tumor suppressors, haematological malignancies, potential therapeutic applications
Abstract: MicroRNAs (miRNAs) are an abundant class of approximately 22-nucleotide – noncoding RNAs, which play important regulatory roles in animal and plant development: they are involved in gene expression at the posttranscriptional level by degrading or blocking translation of messenger RNA (mRNA) targets. miRNAs can induce RNA cleavage and chromatin modifications, and are implicated in apoptotic pathways and regulation of cell growth and proliferation. It is becoming clear that miRNAs play important roles in the regulation of gene expression during development, and our knowledge of the expression levels or function of miRNAs in normal and neoplastic cells is increasing. Accumulating experimental evidence suggests that different miRNAs are deregulated in primary human tumors and that many human miRNAs are located at genomic regions linked to cancer. miRNAs may be important regulators of mammalian hematopoiesis. They are involved in a variety of hematological malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and primary effusion lymphoma. Here, we provide background on the biogenesis and function of miRNAs and discuss potential therapeutic applications of miRNA-based technology in hematological malignancies.
Export Options
About this article
Cite this article as:
Barbarotto Elisa and Calin A. George, Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies, Current Pharmaceutical Design 2008; 14(21) . https://dx.doi.org/10.2174/138161208785294627
DOI https://dx.doi.org/10.2174/138161208785294627 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Synthesis and Biological Study of Novel Indole-3-Imine-2-on Derivatives as Src Kinase and Glutathione S-Transferase Inhibitors
Letters in Drug Design & Discovery TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Necrotizing Enterocolitis: Clinical Features, Histopathological Characteristics, and Genetic Associations
Current Pediatric Reviews Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine Phosphorylation-Specific Prolyl Isomerase Pin1 as a new Diagnostic and Therapeutic Target for Cancer
Current Cancer Drug Targets Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Chemical and Medicinal Versatility of Dithiocarbamates: An Overview
Mini-Reviews in Medicinal Chemistry Immune Responses to Gene-Modified T Cells
Current Gene Therapy Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Anticancer Agents: VTA or VDA
Current Bioactive Compounds Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma
Current Cancer Drug Targets Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Idarubicin and Ara-C Treatment Associated with Fungal Infection in Acute Leukemia Patients with Febrile Neutropenia
Clinical Cancer Drugs The Proteasome as a Therapeutic Target for Lung Fibrosis
Current Enzyme Inhibition Tumor Stroma Manipulation By MSC
Current Drug Targets